AbbVie signs cancer drug development deal with up to $2.5B in milestones

Advertisement

North Chicago, Ill.-based AbbVie has entered a collaboration and option-to-license agreement with Cologne, Germany-based DISCO Pharmaceuticals to develop cancer therapies targeting solid tumors, DISCO announced Nov. 19.

Under the agreement, DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in option, development and other milestone payments, plus tiered royalties on worldwide net sales.

The companies will combine DISCO’s DISCOtech platform, which identifies pairs of proteins on cancer cell surfaces, with AbbVie’s oncology research and development capabilities. The collaboration will focus on developing AND-gated bispecific therapies, which DISCO said are designed to recognize two tumor targets simultaneously and potentially reduce damage to healthy tissue.

AbbVie will have the option to exclusively license selected programs for further development after DISCO completes specified research activities.

DISCO is also advancing its own therapies for small cell lung cancer and colorectal cancer toward clinical development.

Advertisement

Next Up in Pharmacy

Advertisement